SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is ...

I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...

Mylan N.V., Sandoz, Inc, Bausch Health Companies Inc., Purdue Pharma L.P., and Endo International Plc What Major Trends Are Fueling The Growth Of The Prescription Pain Medication Market? These ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

The FDA launched an artificial intelligence tool Monday dubbed Elsa, with Commissioner Marty Makary hyping the effort’s early ...

Pharma companies involved in Vietnam are making more strategic moves to ease potential impacts in the face of US tariff ...